Profile data is unavailable for this security.
About the company
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Company’s products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
- Revenue in TWD (TTM)13.82bn
- Net income in TWD4.80bn
- Incorporated2000
- Employees131.00
- LocationPharmaEssentia Corp13FNo.3, Yuanqu Street, Nankang DistrictTAIPEI 115TaiwanTWN
- Phone+886 226557688
- Fax+886 226557626
- Websitehttps://www.pharmaessentia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insilico Medicine Cayman TopCo | 1.68bn | -1.39bn | 176.43bn | -- | -- | -- | -- | 104.94 | -0.6217 | -0.6217 | 0.7515 | -9.55 | -- | -- | -- | -- | -- | -- | -- | -- | 83.56 | -- | -82.72 | -- | -- | -- | -- | -- | 67.71 | -- | 91.92 | -- | -- | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 21.60bn | 9.00bn | 195.49bn | 1.42k | 21.72 | 6.63 | -- | 9.05 | 4.41 | 4.41 | 10.57 | 14.44 | 0.7497 | 5.75 | 13.98 | 3,357,423.00 | 31.24 | 10.89 | 34.76 | 11.75 | 95.37 | 96.19 | 41.68 | 27.72 | 5.34 | -- | 0.0006 | 24.71 | 76.29 | 462.87 | 121.97 | -- | 24.77 | -- |
| Biocon Ltd | 58.15bn | 2.09bn | 212.82bn | 3.44k | 78.42 | -- | 24.55 | 3.66 | 4.85 | 4.85 | 133.23 | -- | -- | -- | -- | 48,888,440.00 | -- | 2.72 | -- | 3.92 | 65.74 | 62.04 | 3.74 | 8.83 | -- | 1.66 | -- | 9.26 | 3.43 | 19.36 | -0.8998 | 5.45 | 4.99 | -- |
| Shanghai Bao Pharmaceuticals Co Ltd | 211.86m | -1.73bn | 220.85bn | -- | -- | 54.68 | -- | 1,042.43 | -1.32 | -1.32 | 0.1619 | 3.09 | -- | -- | -- | -- | -- | -- | -- | -- | 97.96 | -- | -814.93 | -- | 2.07 | -- | 0.2168 | -- | -11.11 | -- | -127.21 | -- | -- | -- |
| RemeGen Co Ltd | 10.12bn | -4.30bn | 231.11bn | 3.00k | -- | 24.58 | -- | 22.85 | -1.75 | -1.75 | 4.10 | 4.12 | 0.3812 | 0.541 | 6.40 | 742,854.40 | -16.21 | -19.20 | -27.09 | -23.96 | 82.97 | 81.06 | -42.54 | -87.98 | 0.7278 | -9.93 | 0.4848 | -- | 58.54 | 223.78 | 2.84 | -- | 32.40 | -- |
| PharmaEssentia Corp | 13.82bn | 4.80bn | 275.23bn | 131.00 | 55.97 | 8.12 | 53.00 | 19.92 | 12.95 | 12.95 | 37.25 | 89.26 | 0.4345 | 1.23 | 4.84 | -- | 15.11 | -5.26 | 16.67 | -5.99 | 89.17 | 82.30 | 34.78 | -19.83 | 6.54 | 64.89 | 0.0291 | -- | 90.67 | 99.81 | 575.37 | -- | 40.94 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 6.81bn | -3.28bn | 386.16bn | 1.87k | -- | 16.96 | -- | 56.67 | -3.65 | -3.65 | 7.53 | 24.33 | 0.3067 | 4.93 | 13.37 | 924,201.40 | -14.76 | -- | -17.11 | -- | 57.10 | -- | -48.12 | -- | 6.32 | -- | 0.0255 | -- | 25.48 | -- | 53.54 | -- | -- | -- |
| Akeso Inc | 11.40bn | -3.84bn | 388.93bn | 3.53k | -- | 12.97 | -- | 34.12 | -1.08 | -1.08 | 3.24 | 8.11 | 0.2115 | 0.7726 | 3.95 | 935,890.60 | -7.07 | -8.38 | -8.20 | -9.82 | 79.26 | -- | -33.46 | -33.18 | 4.01 | -536.98 | 0.4168 | -- | -53.08 | 97.39 | -125.37 | -- | 34.14 | -- |
Data as of Feb 11 2026. Currency figures normalised to PharmaEssentia Corp's reporting currency: Taiwan Dollar TWD
9.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 10.94m | 2.88% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 8.84m | 2.33% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 3.71m | 0.98% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 2.77m | 0.73% |
| Geode Capital Management LLCas of 12 Feb 2026 | 2.28m | 0.60% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.53m | 0.40% |
| AQR Capital Management LLCas of 30 Sep 2025 | 1.33m | 0.35% |
| Capital Investment Trust Corp.as of 06 Feb 2026 | 1.03m | 0.27% |
| State Street Global Advisors Ltd.as of 05 Feb 2026 | 925.64k | 0.24% |
| Vanguard Asset Management Ltd.as of 31 Dec 2025 | 902.84k | 0.24% |
More ▼
Data from 30 Sep 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
